Improving Cognition Via Exercise in Schizophrenia

Not Applicable

Completed

• Conditions: Schizophrenia and Related Disorders
• Interventions: Behavioral: Stretching and Toning Exercise; Behavioral: Aerobic Exercise

• Registration Number: NCT03270098
• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary

People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime. The goal of the proposed study is to examine the impact of remote exercise training on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.

Detailed Description

The goal of the proposed study is to examine the impact of remote exercise training on cognitive functioning in people with schizophrenia. People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functional outcome and disability, thus representing an important public health concern and a target for interventions. At present, available treatments offer only minimal to limited benefits to ameliorate these deficits. Extensive animal and human research literatures converge in supporting the positive influence of aerobic exercise training on cognitive functioning. Preliminary data indicate that aerobic exercise training is effective in improving cognitive functioning in people with schizophrenia. However, previous studies employed small samples, focused on a single or limited range of cognitive domains, and/or collected insufficient information on daily functioning or putative biomarkers underlying cognitive change. Supported by supplement funding from NIMH, the goal of the proposed study is also to explore the impact of remote exercise training on suicide risk in individuals with schizophrenia. People with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime, and an estimated 5-10% actually being successful in completing suicide. This highly elevated risk represents a serious public health concern and an important target for interventions. However, available treatments offer only minimal to limited benefits to ameliorate this risk. Extensive animal and human research literatures converge in supporting the positive influence of AE training on a number of predictors of suicide risk including depressed mood, sleep difficulties, and poor cognition. Yet, at present there are no studies directly examining the impact of AE on suicide risk in this population.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-08-30
• Study First Submitted QC: 2017-08-30
• Study First Posted: 2017-09-01
• Study Start: 2018-04-26
• Primary Completion: 2023-01-31
• Study Completion: 2023-01-31
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-12
• Last Update Posted: 2023-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

• A DSM-V diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder.
• Age 18-55 years.
• Taking antipsychotic medication for at least 8 weeks and on current doses for 4 weeks, and/or injectable depot antipsychotics with no change in the last 3 months.
• Capacity to understand all the potential risks and benefits of the study.
• Medically cleared by a physician to take part in VO2max tests and aerobic exercise training or stretching-and-toning exercise training.

Read More

Exclusion Criteria

• A DSM-V diagnosis of alcohol/substance abuse (except nicotine) within the last month or a diagnosis of alcohol/substance dependence (except nicotine) within the last 6 months
• Initiation of anti-depressants, mood stabilizers, or other medications known to impact cognition in previous 4 weeks or any change in doses during this period.
• History of seizures/head trauma with loss of consciousness (>10 minutes) resulting in cognitive sequelae.
• Significant clinical abnormalities in physical examination, lab assessments, or ECG.
• Neurological/medical conditions that could interfere with study participation (e.g., unstable cardiac disease, stuttering).
• Body Mass Index (BMI) ≥ 40.
• Untreated hyper- or hypothyroidism.
• Being pregnant or nursing.
• Serious homicidal/suicidal risk (past 6 months).
• "Moderate" or more severe conceptual disorganization (PANSS≥4).
• Poor English reading ability (WTAR<7).
• Participation in a study with cognitive assessment in the past 3 months.
• Serious homicidal risk (past 6 months)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Stretching and Toning Exercise	Stretching and Toning Exercise	Using trainer-led video calls with stretching and toning exercises.
Aerobic Exercise	Aerobic Exercise	Using trainer-led video calls with traditional callisthenic body movements (e.g., jumping jacks, burpees, etc.)

Primary Outcome Measures

Name	Time	Method
Change in VO2Max	Baseline and 12 weeks	VO2Max (maximal oxygen consumption) is an index of the ability to consume oxygen and is a key indicator of aerobic fitness. Change in the VO2Max at 12 weeks as compared to baseline.
Change in the MATRICS Consensus Cognitive Battery (MCCB)	Baseline and 12 weeks	The MCCB is a standardized battery designed to measure cognitive functioning in people with schizophrenia. The MCCB is represented as a composite T score. Change in the MCCB at 12 weeks as compared to baseline.

Secondary Outcome Measures

Name	Time	Method
Serum BDNF	Baseline and 12 weeks	BDNF is extracted from blood samples and serves as a biomarker of exercise-related cognitive changes. Change in the BDNF at 12 weeks as compared to baseline.
Change in Columbia Suicide Severity Rating Scale (C-SSRS)	Baseline and 12 weeks	The C-SSRS is a semi-structured interview that measures 4 suicide risk related domains: ideation severity, ideation intensity, behavior, and lethality. Full scale from 1-10, with higher score indicating more suicidal ideation and behavior. Change in the C-SSRS at 12 weeks as compared to baseline.
Change in the Specific Levels of Functioning Scale (SLOF)	Baseline and 12 weeks	The SLOF is a 43-item survey assessing multiple domains of daily functioning. Total score range from 43 to 215, with higher scores indicating better the overall functioning. Change in the SLOF at 12 weeks as compared to baseline.
Change in the UCSD Performance-based Skills Assessment (UPSA)	Baseline and 12 weeks	The UPSA is performance-based measure of real-world daily functioning abilities. Participants receive scores for multiple domains, which are summed to create a summary score ranging from 0 to 100 with higher score indicating better overall functioning. Change in the UPSA at 12 weeks as compared to baseline.
Change in the Schizophrenia Cognition Rating Scale (SCoRS)	Baseline and 12 weeks	The SCoRS is a 20-item clinician-administered interview assessing cognition-related daily functioning. Each item rated on a 4-point scale ranging from "no impairment" to "severe impairment". Total scores range from 20-80, with higher score indicating poorer functioning. Change in the SCoRS at 12 weeks as compared to baseline.

Trial Locations

Locations (4)

Stanford University; 🇺🇸 Stanford, California, United States

Augusta University; 🇺🇸 Augusta, Georgia, United States

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States

University of North Carolina; 🇺🇸 Chapel Hill, North Carolina, United States